Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
As of close of business last night, ImmunityBio Inc’s stock clocked out at $3.22, down -5.85% from its previous closing price of $3.42. In other words, the price has decreased by -$5.85 from its previous closing price. On the day, 4.2 million shares were traded.
Ratios:
To gain a deeper understanding of IBRX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.64 and its Current Ratio is at 2.68.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on January 10, 2025, initiated with a Buy rating and assigned the stock a target price of $6.
On May 12, 2023, Piper Sandler Downgraded its rating to Neutral which previously was Overweight and also lowered its target price recommendation from $10 to $4.
On August 03, 2022, Jefferies started tracking the stock assigning a Buy rating and target price of $8.Jefferies initiated its Buy rating on August 03, 2022, with a $8 target price.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 320.75.
Stock Price History:
Over the past 52 weeks, IBRX has reached a high of $10.53, while it has fallen to a 52-week low of $2.28. The 50-Day Moving Average of the stock is 5.85%, while the 200-Day Moving Average is calculated to be -30.37%.
Shares Statistics:
A total of 696.83M shares are outstanding, with a floating share count of 76.14M. Insiders hold about 89.57% of the company’s shares, while institutions hold 11.58% stake in the company.
